West Pharmaceutical Services (NYSE:WST) Releases FY 2025 Earnings Guidance

Key Points

• West Pharmaceutical Services has updated its FY 2025 earnings guidance, forecasting earnings per share (EPS) between $7.060 and $7.110, exceeding the analyst consensus estimate of $6.760.
• The company provided revenue guidance of $3.1 billion, which is higher than the consensus estimate of $3.0 billion.
• West Pharmaceutical Services has received a range of ratings from analysts, with an average price target set at $321.89 and a current rating of "Moderate Buy."

West Pharmaceutical Services (NYSE:WST - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 7.060-7.110 for the period, compared to the consensus estimate of 6.760. The company issued revenue guidance of $3.1 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

Analysts Set New Price Targets

Several research firms have recently weighed in on WST. Rothschild Redb raised shares of West Pharmaceutical Services to a "strong-buy" rating in a report on Monday, September 15th. UBS Group raised their price objective on West Pharmaceutical Services from $285.00 to $320.00 and gave the company a "buy" rating in a report on Friday, July 25th. Evercore ISI set a $350.00 price objective on West Pharmaceutical Services in a report on Tuesday, October 7th. Weiss Ratings reissued a "hold (c)" rating on shares of West Pharmaceutical Services in a report on Tuesday, October 14th. Finally, Barclays boosted their target price on shares of West Pharmaceutical Services from $260.00 to $275.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $321.89.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $276.87 on Thursday. West Pharmaceutical Services has a 52-week low of $187.43 and a 52-week high of $352.33. The firm has a market capitalization of $19.91 billion, a price-to-earnings ratio of 41.45, a PEG ratio of 4.90 and a beta of 1.07. The company has a fifty day simple moving average of $257.04 and a 200-day simple moving average of $232.65. The company has a quick ratio of 2.08, a current ratio of 2.78 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, topping analysts' consensus estimates of $1.51 by $0.33. West Pharmaceutical Services had a return on equity of 18.43% and a net margin of 16.48%.The firm had revenue of $766.50 million for the quarter, compared to the consensus estimate of $725.11 million. During the same quarter last year, the business posted $1.52 earnings per share. The firm's revenue was up 9.2% compared to the same quarter last year. On average, equities analysts anticipate that West Pharmaceutical Services will post 6.62 EPS for the current fiscal year.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of institutional investors have recently added to or reduced their stakes in the stock. Benjamin Edwards Inc. raised its holdings in West Pharmaceutical Services by 1.7% in the second quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier's stock valued at $661,000 after acquiring an additional 50 shares in the last quarter. Modern Wealth Management LLC raised its holdings in West Pharmaceutical Services by 7.4% in the second quarter. Modern Wealth Management LLC now owns 1,270 shares of the medical instruments supplier's stock valued at $278,000 after acquiring an additional 87 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new stake in West Pharmaceutical Services during the 2nd quarter worth about $25,000. Acadian Asset Management LLC lifted its holdings in West Pharmaceutical Services by 14.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier's stock worth $284,000 after buying an additional 157 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in West Pharmaceutical Services by 78.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier's stock worth $98,000 after buying an additional 197 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company's stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.